• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by CorMedix Inc.

    11/13/25 4:57:39 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CRMD alert in real time by email
    S-8 1 ea0264891-s8_cormedix.htm REGISTRATION STATEMENT

    As filed with the Securities and Exchange Commission on November 13, 2025

    Registration Statement No. 333-         

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

     

     

    CORMEDIX INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   20-5894890

    (State of other jurisdiction of

    incorporation or organization)

     

    (I.R.S. Employer

    Identification No.)

     

    CorMedix Inc.

    300 Connell Drive, Suite 4200

    Berkeley Heights, NJ 07922

    (Address of principal executive offices) (Zip code)

     

     

     

    Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan

    (Full title of the plan)

     

     

     

    Joseph Todisco

    Chief Executive Officer

    CorMedix Inc.

    300 Connell Drive, Suite 4200

    Berkeley Heights, New Jersey 07922

    Telephone: (908) 517-9500

    (Name, address, including zip code, and telephone number, including area code, of agent for service) 

     

     

     

    Copies to:

     

    Jared Fertman

    Andrew Marmer

    Willkie Farr and Gallagher LLP

    787 Seventh Ave

    New York, New York 10019

    Telephone: (212) 728-8000

     

     

     

    Indicate by check mark whether the Registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Act. (Check one):

     

      Large accelerated filer ☐ Accelerated filer ☐
      Non-accelerated filer ☒ Smaller reporting company ☒
          Emerging Growth Company ☐

     

    If an emerging growth company, indicate by check mark if the Registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement relates to the registration of an additional 7,672,000 shares of common stock, $0.001 par value per share (“Common Stock”), of CorMedix Inc. (the “Registrant”), for issuance under the Amended and Restated CorMedix Inc 2019 Omnibus Stock Incentive Plan (the “Plan”). The shares of Common Stock are securities of the same class and related to the same employee benefit plan, the Plan, as amended and restated on October 13, 2022, as those registered pursuant to the Registrant’s registration statement on Form S-8, previously filed with the Securities and Exchange Commission (the “Commission”) on November 9, 2010, December 13, 2013, August 7, 2016, December 17, 2019 and October 26, 2022.

     

    The Board of Directors of the Registrant approved an amendment to the Plan on September 17, 2024 and October 7, 2024 and the Registrant’s stockholders approved the amendment at the Registrant’s 2024 Annual Meeting of Stockholders on November 21, 2024 (“Amendment No. 1”). The Board of Directors of the Registrant approved a second amendment to the Plan on September 14, 2025 and the Registrant’s stockholders approved the amendment at the Registrant’s Special Meeting of Stockholders on November 10, 2025 (“Amendment No. 2” and, together with Amendment No. 1, the “Amendments”). The Amendments increased the number of shares of Common Stock reserved and available for issuance under the Plan by the number of shares being registered herein.

     

    In accordance with General Instruction E of Form S-8, the contents of the Registrant’s registration statements on Form S-8 (file numbers 333-170498, 333-192840, 333-212430, 333-235556 and 333-268019) filed with the Commission on November 9, 2010, December 13, 2013, August 7, 2016, December 17, 2019 and October 26, 2022, respectively, are incorporated herein by reference and the information required by Part II is omitted, except as supplemented by the information set forth below.

     

     

     

    PART I

    INFORMATION REQUIRED IN THE SECTION 10(a) PROSPECTUS

     

    Item 1. Plan Information.

     

    The information required by Item 1 is included in documents sent or given by the Registrant to participants in the plan covered by the registration statement pursuant to Rule 428(b)(1) of the Securities Act of 1933, as amended (the “Securities Act”) and the introductory note to Part I of Form S-8.

     

    Item 2. Registrant Information and Employee Plan Annual Information.

     

    The written statement required by Item 2 is included in documents sent or given by the Registrant in the plan covered by this Registration Statement pursuant to Rule 428(b)(1) of the Securities Act.

     

    - 1 -

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference.

     

    The following documents previously filed by the Registrant with the Commission are hereby incorporated by reference into this Registration Statement:

     

    (i)The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024 (filed with the Commission on March 25, 2025);

     

    (ii)The Registrant ’s Quarterly Reports on Form 10-Q for the quarterly periods ended March 31, 2025, June 30, 2025 and September 30, 2025 (filed with the Commission on May 6, 2025, August 7, 2025 and November 12, 2025, respectively);

     

    (iii)The Registrant ’s Current Reports on Form 8-K filed with the Commission on January 7, 2025, March 25, 2025, April 8, 2025, April 22, 2025, May 6, 2025, June 23, 2025, June 25, 2025, June 30, 2025, August 7, 2025, August 12, 2025, September 2, 2025 (as amended on September 30, 2025), October 20, 2025 and November 12, 2025; and

     

    (iv)The description of the Registrant’s common stock, par value $0.001 per share contained in the Registrant’s Registration Statement on Form 8-A, dated and filed with the Commission on February 2, 2021, as updated by Exhibit 4.5 to our Form 10-K for the fiscal year ended December 31, 2019, and including any amendments or reports filed with the Commission for the purpose of updating such description.

     

    To the extent that any information contained in any Current Report on Form 8-K, or any exhibit thereto, was furnished to, rather than filed with, the Commission, such information or exhibit is specifically not incorporated by reference.

     

    All reports and other documents that the Registrant subsequently files with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended, after the date of this Registration Statement and prior to the filing of a post-effective amendment that indicates that the Registrant has sold all of the securities offered under this Registration Statement or deregisters the distribution of all such securities then remaining unsold shall be deemed to be incorporated by reference in this Registration Statement and to be a part hereof from the date that the Registrant files such report or document.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained herein or in any other subsequently filed document that also is, or is deemed to be, incorporated by reference herein modifies or supersedes such statement. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

    II-1

     

    Item 8. Exhibits.

     

    The Exhibits to this Registration Statement are listed in the Index to Exhibits and are incorporated herein by reference.

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    5.1*   Opinion of Willkie Farr & Gallagher LLP
    23.1*   Consent of Willkie Farr & Gallagher LLP (included as part of Exhibit 5.1)
    23.2*   Consent of Marcum LLP, Independent Registered Accounting Firm of  CorMedix, Inc.
    23.3*   Consent of EisnerAmper LLP, Independent Registered Accounting Firm of Melinta Therapeutics, LLC
    24.1*   Power of Attorney (included on the signature page of this Registration Statement)
    99.1   Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit 99.1 to the Form S-8 filed with the Commission on October 26, 2022)
    99.2   Amendment No. 1 to the Amended and Restated CorMedix Inc. 2019 Omnibus Stock Incentive Plan (Incorporated by reference to Appendix A to CorMedix Inc.'s Proxy Statement on Schedule 14A dated October 8, 2024. See SEC File Number 001-34673)
    99.3   Amendment No. 2 to the CorMedix Inc. Amended & Restated 2019 Omnibus Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Form 10-Q filed with the Commission on November 12, 2025).
    107*   Calculation of Filing Fee Table

     

    *Filed herewith

     

    II-2

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the Town of Berkeley Heights, State of New Jersey, on the 13 day of November 2025.

     

      CORMEDIX INC.
       
      By: /s/ Joseph Todisco
        Joseph Todisco
        Chief Executive Officer

     

    POWER OF ATTORNEY

     

    Each person whose signature appears below constitutes and appoints Joseph Todisco and Susan Blum, or each of them singly, with fully power to act without the other, his or her true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this Registration Statement, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorney-in-fact and agent full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he might or could do in person, hereby ratifying and confirming all that said attorney-in-fact and agent, or his substitute or substitutes, may lawfully do or cause to be done by virtue hereof.

     

    Pursuant to the requirements of the Securities Act of 1933, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
    /s/ Joseph Todisco   Director and Chief Executive Officer
    (Principal Executive Officer)
      November 13, 2025
    Joseph Todisco        
             
    /s/ Susan Blum   Chief Financial Officer
    (Principal Financial Officer and
    Principal Accounting Officer)
      November 13, 2025
    Susan Blum        
             
    /s/ Myron Kaplan   Director and Chairman of the Board   November 13, 2025
    Myron Kaplan        
             
    /s/ Janet Dillione   Director   November 13, 2025
    Janet Dillione        
             
    /s/ Gregory Duncan   Director   November 13, 2025
    Gregory Duncan        
             
    /s/ Alan W. Dunton   Director   November 13, 2025
    Alan W. Dunton        
           
    /s/ Steven Lefkowitz   Director   November 13, 2025
    Steven Lefkowitz        
             
    /s/ Robert Stewart   Director   November 13, 2025
    Robert Stewart        

     

    II-3

    Get the next $CRMD alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $CRMD

    DatePrice TargetRatingAnalyst
    10/20/2025$14.00Hold → Buy
    D. Boral Capital
    6/30/2025Buy → Hold
    D. Boral Capital
    6/30/2025$20.00Buy
    H.C. Wainwright
    3/7/2025$18.00Outperform
    Leerink Partners
    1/13/2025$15.00Buy
    D. Boral Capital
    8/26/2024$13.00Buy
    Rodman & Renshaw
    8/10/2023$6.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $CRMD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Strong Earnings and Biotech Resilience Define the Midweek Momentum

    DENVER, Nov. 12, 2025 (GLOBE NEWSWIRE) -- Kraig Labs (OTCQB:KBLB) Spins the Future — Decades of Failure Give Way to a Commercial Breakthrough After decades of failed attempts by corporate giants and research consortia across the globe, Kraig Biocraft Laboratories (OTCQB:KBLB) appears poised to crack biotechnology's most persistent challenge: scalable, high-performance recombinant spider silk. Kraig's imminent shipments of spider silk fiber and fabric samples to fashion and performance textile partners signal a watershed moment. Unlike fermentation-based methods that have frustrated even DuPont, BASF, and Bolt Threads, Kraig's innovation lies in reprogramming silkworms themselves to spi

    11/12/25 11:00:36 AM ET
    $CRMD
    $HUMA
    $SLRX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)

    CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

    ‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its business. Recent Corporate Highlights:

    11/12/25 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    November 17, 2023 - FDA Roundup: November 17, 2023

    For Immediate Release: November 17, 2023 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, to mark the 15th anniversary of the FDA foreign offices, the FDA published an interview with Susan Winckler, who was FDA chief of staff when the first office was opened in Beijing on November 19, 2008. Winckler is now CEO of the Reagan-Udall Foundation

    11/17/23 4:18:44 PM ET
    $BMY
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approval for DEFENCATH issued to CORMEDIX INC

    Submission status for CORMEDIX INC's drug DEFENCATH (ORIG-1) with active ingredient TAUROLIDINE AND HEPARIN SODIUM has changed to 'Approval' on 11/15/2023. Application Category: NDA, Application Number: 214520, Application Classification: Type 1 - New Molecular Entity and Type 4 - New Combination

    11/15/23 9:53:06 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaplan Myron bought $275,500 worth of shares (25,000 units at $11.02), increasing direct ownership by 14% to 201,034 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    10/27/25 9:30:10 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP, Chief Commercial Officer Mistry Erin bought $14,985 worth of shares (1,500 units at $9.99), increasing direct ownership by 3% to 52,011 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    12/13/24 4:15:22 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Todisco Joseph bought $50,718 worth of shares (13,561 units at $3.74), increasing direct ownership by 4% to 352,839 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    3/14/24 8:45:21 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    SEC Filings

    View All

    SEC Form S-8 filed by CorMedix Inc.

    S-8 - CorMedix Inc. (0001410098) (Filer)

    11/13/25 4:57:39 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 10-Q filed by CorMedix Inc.

    10-Q - CorMedix Inc. (0001410098) (Filer)

    11/12/25 8:21:01 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - CorMedix Inc. (0001410098) (Filer)

    11/12/25 7:42:23 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Kaplan Myron bought $275,500 worth of shares (25,000 units at $11.02), increasing direct ownership by 14% to 201,034 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    10/27/25 9:30:10 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Duncan Gregory Scott exercised 13,333 shares at a strike of $8.32, increasing direct ownership by 53% to 38,333 units (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    9/18/25 9:45:02 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Dunton Alan W exercised 10,000 shares at a strike of $3.55 and sold $131,300 worth of shares (10,000 units at $13.13) (SEC Form 4)

    4 - CorMedix Inc. (0001410098) (Issuer)

    9/16/25 9:45:02 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cormedix upgraded by D. Boral Capital with a new price target

    D. Boral Capital upgraded Cormedix from Hold to Buy and set a new price target of $14.00

    10/20/25 9:02:46 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Cormedix downgraded by D. Boral Capital

    D. Boral Capital downgraded Cormedix from Buy to Hold

    6/30/25 8:42:52 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Cormedix with a new price target

    H.C. Wainwright initiated coverage of Cormedix with a rating of Buy and set a new price target of $20.00

    6/30/25 8:34:13 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by CorMedix Inc.

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    11/14/24 4:34:05 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by CorMedix Inc. (Amendment)

    SC 13G/A - CorMedix Inc. (0001410098) (Subject)

    2/14/24 10:37:21 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by CorMedix Inc.

    SC 13G - CorMedix Inc. (0001410098) (Subject)

    2/13/24 5:02:29 PM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Leadership Updates

    Live Leadership Updates

    View All

    Talphera Announces the Appointment of Joe Todisco to Board of Directors

    SAN MATEO, Calif., Oct. 21, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), (Talphera), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced the appointment of Joe Todisco, the CEO of CorMedix Inc. (NASDAQ:CRMD) to its Board of Directors. In September 2025, CorMedix made a strategic investment in Talphera as part of the company's private placement financing. In connection with the closing of this transaction, CorMedix has the right to nominate a representative to the Talphera Board of Directors. The Company also provided CorMedix with a 60-day exclusive negotiation period follo

    10/21/25 8:30:00 AM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Announces Appointment of Chief Legal Officer

    BERKELEY HEIGHTS, N.J., Dec. 15, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced the appointment of Beth Zelnick Kaufman, Esq. as EVP, Chief Legal Officer, and Corporate Secretary, effective December 12, 2023. The Company also announced that, upon mutual agreement with the Company, Dr. Phoebe Mounts will no longer serve as the Company's General Counsel, effective December 12, 2023, and will be separating from CorMedix effective December 31, 2023, to pursue other opportunities. Ms. Zelnick Kaufman has

    12/15/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Announces Partnership With The Leapfrog Group

    – CorMedix to advocate for patient safety and infection prevention as part of Leapfrog's Partners Advisory Committee BERKELEY HEIGHTS, N.J., Dec. 04, 2023 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening diseases and conditions, today announced an agreement with The Leapfrog Group, an independent national watchdog organization of employers and other purchasers focused on health care safety, whereby CorMedix Inc. will become a member of the Leapfrog Partners Advisory Committee. The Partners Advisory Committee is a platform for the crea

    12/4/23 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $CRMD
    Financials

    Live finance-specific insights

    View All

    Talphera Announces Third Quarter 2025 Financial Results and Provides Corporate Update

    Closed $17 million first tranche financing led by a strategic investment from CorMedix, Inc. Cash and investments at September 30, 2025 were $21.3 million; combined with conditional future tranches of previous financings, expect sufficient cash through a potential PMA approval of Niyad in late 2026 5 of the 9 target profile clinical sites are now activated; completion of NEPHRO study expected in H1 2026 Conference call and webcast to be held Wednesday, November 12, 2025 at 4:30 pm ET SAN MATEO, Calif., Nov. 12, 2025 /PRNewswire/ -- Talphera, Inc. (NASDAQ:TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use i

    11/12/25 4:05:00 PM ET
    $CRMD
    $TLPH
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. Reports Third Quarter 2025 Financial Results and Updates FY 2025 Guidance

    ‒ Q3 2025 Net Revenue of $104.3 million; Pro Forma Net Revenue of $130.8 million ‒ ‒ Q3 2025 Net Income of $108.6 million; Adjusted EBITDA of $71.9 million ‒ ‒ FY 2025 Pro Forma Net Revenue Guidance Raised to a Range of $390 to $410 million ‒ ‒ Conference Call Scheduled for Today at 8:30 a.m. Eastern Time ‒ BERKELEY HEIGHTS, N.J., Nov. 12, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced financial results for the third quarter ended September 30, 2025 and provided an update on its business. Recent Corporate Highlights:

    11/12/25 7:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    CorMedix Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on November 12, 2025

    BERKELEY HEIGHTS, N.J., Oct. 31, 2025 (GLOBE NEWSWIRE) -- CorMedix Inc. (NASDAQ:CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced that it will report its financial results for the third quarter ended September 30, 2025, before the market opens on Wednesday, November 12, 2025, and will host a corporate update conference call at 8:30am Eastern Time. Wednesday, November 12th @ 8:30am ETDomestic:1-844-676-2922International:1-412-634-6840Webcast:Webcast Link About CorMedixCorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the

    10/31/25 8:30:00 AM ET
    $CRMD
    Biotechnology: Pharmaceutical Preparations
    Health Care